EcoDrugPlus

C-X-C Motif Chemokine Receptor 4

Ensembl ID : ENSSPAG00000006989
Gene Symbol: CXCR4
3 Cross references
201 Possible Orthologues:

C-Reactive Protein-Like

Ensembl ID : ENSSPAG00000020692
Gene Symbol: LOC103375648
2 Cross references
382 Possible Orthologues:

C-Reactive Protein-Like

Ensembl ID : ENSSPAG00000002669
Gene Symbol: LOC103353884
2 Cross references
394 Possible Orthologues:

C-Reactive Protein-Like

Ensembl ID : ENSSPAG00000002719
Gene Symbol: LOC103353887
2 Cross references
382 Possible Orthologues:

C-Reactive Protein-Like

Ensembl ID : ENSSPAG00000020710
Gene Symbol: LOC103375649
2 Cross references
382 Possible Orthologues:

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSSPAG00000008983
Gene Symbol: CFTR
3 Cross references
214 Possible Orthologues:

D(4) Dopamine Receptor-Like

Ensembl ID : ENSSPAG00000004103
Gene Symbol: LOC103374573
3 Cross references
181 Possible Orthologues:

Dna Methyltransferase 1

Ensembl ID : ENSSPAG00000000468
Gene Symbol: DNMT1
3 Cross references
210 Possible Orthologues:

Dna Topoisomerase 1-Like

Ensembl ID : ENSSPAG00000021140
Gene Symbol: LOC103365891
3 Cross references
207 Possible Orthologues:

Dna Topoisomerase I

Ensembl ID : ENSSPAG00000000920
Gene Symbol: TOP1
3 Cross references
198 Possible Orthologues:

Dna Topoisomerase Ii Alpha

Ensembl ID : ENSSPAG00000023372
Gene Symbol: TOP2A
3 Cross references
209 Possible Orthologues:

Dna Topoisomerase Ii Beta

Ensembl ID : ENSSPAG00000006447
Gene Symbol: TOP2B
3 Cross references
207 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).